Carcinoma, Pancreatic Ductal
Conditions
Brief summary
Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis.
Detailed description
Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis. Initially four equal doses of ParvOryx will be administered intravenously on four consecutive days. Seven to fourteen days after the first intravenous administration the drug will be injected directly in a hepatic metastasis of the pancreatic cancer.
Interventions
DRUGParvovirus H-1 (H-1PV)
Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer. The total dose levels are: 1E09, 5E09 and 1E10 pfu.
Sponsors
Oryx GmbH & Co. KG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age at least 18 year, 2. Ability to give informed consent, 3. Histologically confirmed pancreatic ductal adenocarcinoma (PAD) with at least one measurable hepatic metastasis according to RECIST 1.1, 4. Disease progression despite first line therapy (whatever chemotherapy regimen), 5. Eligibility for second line chemotherapy with gemcitabine, 6. ECOG performance scale 0 or 1, 7. Consent for the sampling and investigations of biological specimens as scheduled by the trial protocol, 8. Adequate bone marrow function: neutrophils \>1.5 x 1E09/L, platelets \>100 x 1E09/L, hemoglobin \>9.0 g/dL, 9. Liver function tests (LFT) within the following range: Bilirubin \<3 x ULN (Upper Limit of Normal); ASAT and ALAT \<5 x ULN, 10. Adequate renal function: Creatinine \<1.5 g/dL, 11. Adequate blood clotting: aPTT \<39 sec, INR \<1.2, 12. Normal thyroid function, i.e. TSH, fT3 and fT4 within the normal range (TSH: 0.4 - 4.0 mU/l, fT3: 2.0 - 4.2 ng/l, fT4: 8 - 18 ng/l) 13. Negative serology for HIV, HBV and HCV, 14. Negative Beta-HCG test in blood in woman of childbearing potential, 15. Use of adequate contraception in both genders, i.e. use of double-effective method of contraception for the entire participation in the trial.
Exclusion criteria
1. Eligibility for surgical treatment, 2. Symptomatic cerebral, pulmonal, and/or osseous metastases, 3. Peritoneal carcinosis, 4. Liver cirrhosis, 5. Splenectomy, 6. Relevant respiratory impairment, corresponding to the grade IV or V of the MRC Breathlessness Scale (stops for breath after walking about 100 meters or after a few minutes on level ground, or too breathless to leave the house, or breathless when undressing), 7. Positive anti-drug antibodies (ADAs) against ParvOryx, 8. Hospitalization due to other conditions than the pancreatic cancer within the last 3 months, 9. Chemotherapy within 2 weeks prior to the first administration of the IMP, 10. Signs of active, systemic infection within 7 days prior to the study inclusion (clinical symptoms (cough, running nose, burning sensation while urinating, apparent skin or wound infection) and/or increase of fever and/or deterioration of infection-specific laboratory parameters beyond changes apparently driven by the underlying pancreatic cancer), 11. Radiotherapy within 6 weeks prior to the study inclusion, 12. Contraindications for CT, 13. Known allergy to iodinated contrast media, 14. Participation in another interventional trial within the last 30 days, 15. Presumed contact with pregnant women and/or infants \<12 months of age within two months after the first administration of the IMP.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Shedding of viral genomes [Vg] | Up to 6 months after treatment beginning | Parameter: Concentration of Vg in feaces |
| Safety and tolerability of the IMP | Up to 6 months after treatment beginning | Parameter: findings in physical examinations |
| Humoral immuneresponse to the IMP | Up to 6 months after treatment beginning | Parameter: Serum concentration of anti-drug antibodies (ADA) |
| Pharmacokinetics of viral genomes [Vg] | Up to 6 months after treatment beginning | Parameter: Cmax in blood |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Histo-immuno-pathological effects of the IMP in the hepatic metastasis | Up to 2 months after treatment beginning | Parameter: extent of tumor necrosis |
| Extent of virus replication in the hepatic metastasis | Up to 2 months after treatment beginning | Parameters: quantification of NS-1 protein in the metastatic tissue |
| Cellular immune response against viral proteins | Up to 6 months after treatment beginning | Parameter: ELISPOT |
| Clinical outcome | Up to 6 months after treatment beginning | Parameters: PFS, OS |
Countries
Germany
Outcome results
None listed